|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,470.00 KRW | +4.59% |
|
+18.91% | -19.79% |
| 12-09 | GC Genome Study Identifies 'Confounders' Interfering with Cancer Signals to Improve Liquid Biopsy Accuracy | CI |
| 12/06/25 | GC Genome Shares Decline Nearly 3% After Strong Kosdaq Debut | MT |
Business description: GC Genome Corporation

Executive Committee: GC Genome Corporation
| Manager | Title | Age | Since |
|---|---|---|---|
Chang-Seok Gi
CEO | Chief Executive Officer | 57 | 26/03/2020 |
Sang-Hun Jeong
DFI | Director of Finance/CFO | 50 | 27/03/2025 |
Seu-Nga Hyun
AUD | Comptroller/Controller/Auditor | 45 | 29/03/2024 |
Eun-Hae Jo
PRN | Corporate Officer/Principal | 52 | - |
Composition of the Board of Directors: GC Genome Corporation
| Director | Title | Age | Since |
|---|---|---|---|
Sang-Uk Kim
BRD | Director/Board Member | 57 | 30/03/2023 |
Company details: GC Genome Corporation

Medical & Diagnostic Laboratories
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +4.59% | +18.91% | -32.22% | - | 87.76M | ||
| -1.16% | +18.89% | +109.51% | +509.28% | 46.43B | ||
| +0.67% | +3.92% | +20.86% | +48.60% | 25.88B | ||
| +0.67% | +2.47% | -19.02% | -34.52% | 7.76B | ||
| +6.76% | +21.17% | +44.83% | +145.26% | 5.69B | ||
| +1.16% | +2.56% | +22.50% | +63.98% | 3.39B | ||
| +1.04% | +19.61% | -25.92% | +1,240.45% | 2.3B | ||
| +0.36% | +8.76% | +186.72% | +12.21% | 2.13B | ||
| +6.83% | +11.49% | +2.48% | -53.01% | 1.99B | ||
| +4.04% | +15.84% | +33.80% | -8.80% | 1.84B | ||
| Average | +2.37% | +8.13% | +34.35% | +213.72% | 9.75B | |
| Weighted average by Cap. | +0.25% | +9.95% | +63.69% | +291.89% |
Sector
Annual profits - Rate of surprise
- Stock Market
- Stocks
- A340450 Stock
- Company GC Genome Corporation
Select your edition
All financial news and data tailored to specific country editions

















